Department of Health Statistics, College of Public Health, Tianjin Medical University, 22 Qi-Xiang-Tai Road, Heping District, Tianjin, 300070, People's Republic of China.
To evaluate the effectiveness comparing the combination of TACE with local ablative therapy and monotherapy on the treatment of HCC using meta-analytical techniques.
Randomized controlled trials and clinical studies comparing TACE plus local ablative therapy with monotherapy for HCC were included in this meta-analysis. Response rate, 1-, 2-, 3-, and 5-year survival rate, and overall survival (OS) were analyzed and compared.
Eighteen studies included a total of 2,120 patients with HCC 1,071 and 1,049 patients for treatment with combination therapy and monotherapy, respectively. The combination therapy group had a significantly better survival in terms of 1-, 2-, 3-, and 5-year survival rate (RR 1.10, 95 % CI 1.03-1.18, P = 0.005; RR 1.20, 95 % CI 1.10-1.30, P < 0.0001; RR 1.43, 95 % CI 1.18-1.73, P < 0.0001; RR 1.40, 95 % CI 1.22-1.61, P < 0.0001, respectively), OS (HR 0.66, 95 % CI 0.51-0.85, P = 0.001), and response rate (RR 1.54, 95 % CI 1.09-2.18, P = 0.013) than that monotherapy group in patients with HCC.
The meta-analysis indicates that the combination of TACE with local ablative therapy was superior to monotherapy in the treatment for patients with HCC.